Remove Cannabis Remove Clinical Trials Remove DEA Remove History
article thumbnail

ASA offers solution to DOJ research block: Our comments on the DEA’s proposed rules

Americans for Safe Access

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.

DEA 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

MAPS, The Multidisciplinary Association for Psychedelic Substances, was awarded a $12,979,050 million grant from the state of Michigan to fund a study on PTSD and cannabis on August 10. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.

article thumbnail

FDA CBD Regulations Are On the Way (Sorta)

Canna Law Blog

A little CBD history. Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”). The future of FDA CBD regulations.

CBD 78
article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105
article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). The rollercoaster starts here!

article thumbnail

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .